Kv1.3 channel blocker, PAP-1, reduces cerebral ischemia-reperfusion injury by remodeling the M1/M2 phenotype and inhibiting the activation of microglia NLRP3 inflammasome. Here, NLRP3 is linked to Cerebral ischemia.